Snyder, Richard O: Courtesy Associate Professor
Recombinant adeno-associated virus (rAAV) vector genome structure and regulation in vivo, biodistribution, AAV capsid structure in solution, and vector manufacturing and testing technology.
Recombinant adeno-associated viral (rAAV) vectors are capable of mediating long-term gene expression following administration to a variety of tissues. In rodent skeletal muscle, the vector genomes persist in the nucleus in concatemeric episomal forms. In non-human primates, rAAV vectors integrate inefficiently into the chromosomes of myocytes and reside predominantly as episomal monomeric and concatemeric circles. A goal of the lab is to understand how episomal rAAV vector genomes and vector gene expression persist long-term in vivo. We have shown that the episomal rAAV genomes assimilate into chromatin with a typical nucleosomal pattern. The persistence of the vector genomes and gene expression for years in quiescent tissues suggests that a bona fide chromatin structure is important for episomal maintenance and transgene expression.
A second goal of the lab is to determine the smallest dose of a rAAV vector injected intramuscularlly that is able to be detected in blood, and to discern the relationship between injected dose and longevity in blood. The tests we are developing involve the collection of blood and the analysis of DNA by PCR and qPCR assays. Validation of all of the steps involved (blood collection, DNA extraction, transport, and PCR analysis) is necessary. Data generated in the non-human primate is the basis for developing a legally defensible commercial qPCR assay that will eventually be used to test athletes. Given that gene transfer technology encompasses a variety of vectors, transgenes, expression cassettes, routes of administration, as well as injection formulations, vector biodistribution can vary widely, thus an outcome of our work will be to better define assays that can be utilized to elucidate vector distribution for legitimate gene therapy applications.
A third goal is to understand the structure of the AAV capsid in solution using molecular methods. Proteolytic mapping of AAV provides a useful tool for gaining a better understanding of dynamic structural changes in the capsid that must occur as it performs its various functions during the virus life cycle. For example, different proteolytic signatures are seen between empty and full (DNA-containing) capsids, indicating that DNA packaging can change the capsid surface. Additionally, we have demonstrated that proteolytic mapping can be used as a diagnostic tool to distinguish among different AAV serotypes.
Postdoctoral Fellow, Johns Hopkins University
Ph.D., SUNY Stony Brook
B.A., Washington University
Awards, Professional Service:
Director, Center of Excellence for Regenerative Health Biotechnology
Recipient, Faculty Achievement Recognition Award, University of Florida
Member, ASGT Viral Gene Transfer Vectors Scientific Committee
Consultant, FDA Cellular, Tissue and Gene Therapies Advisory Committee
Member, ISPE University Relations Committee
Chair, AAV2 Reference Standard Working Group
Member, International Advisory Committee, Clinigene
Member, BioFlorida Community Outreach and Education Committee
Ad-hoc Member, NIH Recombinant DNA Advisory Committee
Member, Editorial Board-Journal of Gene Medicine
Member, Editorial Advisory Board-Current Gene Therapy
Member, Advisory Committee for the Santa Fe Community College Biotechnology Laboratory Program
Recipient, National Institutes of Health Postdoctoral Fellowship
Recipient, Sigma Xi Award for Excellence in Research, SUNY at Stony Brook Chapter
MCB 4905/ IDH 4917 Undergraduate research
GMS 6090 BMS Laboratory Rotation
GMS 7191 Research Conference
GMS7979 Advanced Graduate Research
GMS 7980 Doctoral Research
GMS 6059 Gene Therapy from Bench to Bedside, Course Director
GMS 6506 Biologic Drug Development, Course Director
UF College of Medicine MS Program in Medical Sciences, Co-Director